As India's health-conscious consumers increasingly embrace protein-rich diets, nutrition brands are partnering with coffee ...
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced results from two Phase 1/2 ...
After his Donald Trump impersonation went viral, Avinash Agarwal revealed a severe food poisoning scare and urged followers ...
Independent DSMB identifies no safety concerns and recommends continuation of the clinical trial being conducted at the Icahn School of Medicine at Mount Sinai ...
After a double whammy blow, Cynata is “actively reviewing” alternative uses for its Cymerus platform technology. ... Read ...
The Bucharest National Airports Company, the body managing the “Henri Coandă” International Airport, signed the contract for ...
With attention diverted to Lebanon and Iran, Israel carries on its genocide against the Palestinian people and escalates its ...
Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clinical, biomarker and safety results for Biogen’s investigational tau-targeting ASO, following topline ...
Australia’s retail M&A market entered a more selective phase last year, with buyers appearing less focused on growth-only ...
J&J presents new Imaavy data at EAN 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis: Geneva Monday, June 29, 2026, 18:00 Hrs [IST] Johnson & J ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results